These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies. Hu XT; White FJ Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772 [TBL] [Abstract][Full Text] [Related]
43. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009 [TBL] [Abstract][Full Text] [Related]
44. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal. Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870 [TBL] [Abstract][Full Text] [Related]
45. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534 [TBL] [Abstract][Full Text] [Related]
46. Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist. Picard M; Morisset S; Cloix JF; Bizot JC; Guerin M; Beneteau V; Guillaumet G; Hevor TK Neuroscience; 2010 Sep; 169(3):1337-46. PubMed ID: 20580787 [TBL] [Abstract][Full Text] [Related]
49. In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity. Bétry C; Etiévant A; Lambás-Señas L; McCreary AC; Haddjeri N Synapse; 2011 Oct; 65(10):1042-51. PubMed ID: 21446003 [TBL] [Abstract][Full Text] [Related]
50. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Svensson K; Ekman A; Piercey MF; Hoffmann WE; Lum JT; Carlsson A Naunyn Schmiedebergs Arch Pharmacol; 1991 Sep; 344(3):263-74. PubMed ID: 1683686 [TBL] [Abstract][Full Text] [Related]
51. Microdialysis study of striatal dopamine in MPTP-hemilesioned rats challenged with apomorphine and amphetamine. Dombrowski PA; Carvalho MC; Miyoshi E; Correia D; Bortolanza M; Dos Santos LM; Wietzikoski EC; Eckart MT; Schwarting RK; Brandão ML; Da Cunha C Behav Brain Res; 2010 Dec; 215(1):63-70. PubMed ID: 20600337 [TBL] [Abstract][Full Text] [Related]
52. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo. Millan MJ; Rivet JM; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K J Pharmacol Exp Ther; 1995 Jun; 273(3):1418-27. PubMed ID: 7791116 [TBL] [Abstract][Full Text] [Related]